Differential expression profile of CXCR3 splicing variants is associated with thyroid neoplasia. Potential role in papillary thyroid carcinoma oncogenesis?

Authors:
Soledad Urra
Soledad Urra
Centro FONDAP de Regulación Celular y Patología Joaquín V. Luco
Chile
Martin C Fischer
Martin C Fischer
Duke University
United States
Loreto Veliz
Loreto Veliz
Department of Physiology
Paulina Orellana
Paulina Orellana
Clinica Las Condes
Chile
Antonieta Solar
Antonieta Solar
Hospital Clínico de la Pontificia Universidad Católica de Chile
Chile
Karen Bohmwald
Karen Bohmwald
Millennium Institute on Immunology and Immunotherapy
Alexis Kalergis
Alexis Kalergis
Millennium Institute on Immunology and Immunotherapy
Chile

Oncotarget 2018 Jan 20;9(2):2445-2467. Epub 2017 Dec 20.

Department of Surgical Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

Papillary thyroid cancer (PTC) is the most prevalent endocrine neoplasia. The increased incidence of PTC in patients with thyroiditis and the frequent immune infiltrate found in PTC suggest that inflammation might be a risk factor for PTC development. The CXCR3-ligand system is involved in thyroid inflammation and CXCR3 has been found upregulated in many tumors, suggesting its pro-tumorigenic role under the inflammatory microenvironment. CXCR3 ligands (CXCL4, CXCL9, CXCL10 and CXCL11) trigger antagonistic responses partly due to the presence of two splice variants, CXCR3A and CXCR3B. Whereas CXCR3A promotes cell proliferation, CXCR3B induces apoptosis. However, the relation between CXCR3 variant expression with chronic inflammation and PTC development remains unknown. Here, we characterized the expression pattern of CXCR3 variants and their ligands in benign tumors and PTC. We found that CXCR3A and CXCL10 mRNA levels were increased in non-metastatic PTC when compared to non-neoplastic tissue. This increment was also observed in a PTC epithelial cell line (TPC-1). Although elevated protein levels of both isoforms were detected in benign and malignant tumors, the CXCR3A expression remained greater than CXCR3B and promoted proliferation in Nthy-ori-3-1 cells. In non-metastatic PTC, inflammation was conditioning for the CXCR3 ligands increased availability. Consistently, CXCL10 was strongly induced by interferon gamma in normal and tumor thyrocytes. Our results suggest that persistent inflammation upregulates CXCL10 expression favoring tumor development via enhanced CXCR3A-CXCL10 signaling. These findings may help to further understand the contribution of inflammation as a risk factor in PTC development and set the basis for potential therapeutic studies.

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23502DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788652PMC

Still can't find the full text of the article?

Sign up to send a request to the authors directly.
January 2018
52 Reads

Publication Analysis

Top Keywords

ptc development
12
ptc
10
inflammation risk
8
ptc inflammation
8
cxcr3 ligands
8
papillary thyroid
8
factor ptc
8
non-metastatic ptc
8
risk factor
8
inflammation
6
cxcr3
6
mrna levels
4
tumors ptc
4
benign tumors
4
levels increased
4
ptc cxcr3a
4
cxcr3a cxcl10
4
cxcl10 mrna
4
non-neoplastic tissue
4
ptc epithelial
4

Similar Publications